| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| DTS | Cosmos Limited. | Cosmos Limited | 10.3g | 20 | Powder | KES 210 | |
| DTS | Cosmos Limited. | Cosmos Limited | 10.3g | 100 | Powder | KES 840 | |
| DTS | Cosmos Limited. | Cosmos Limited | 20.6g | 100 | Powder | KES 1,500 | |
| ORS | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 50 | Powder | KES 375 | ||
| ORS | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 1 litre | Powder | KES 375 | ||
| Peditral | G. D. Searle & Co. Ltd. | Laborex Kenya Eurapharma Ltd | Powder | KES 45 | |||
| Unilyte N oral powder | Universal Pharmaceuticals Ltd. | Europa Healthcare Ltd. | 1 litre | Powder | KES 10.65 |
| Oral rehydration salts More info | |
|---|---|
| Mode Of Action | The rationale of oral rehydration therapy is preservation of the facilitated glucose-sodium co-transport system in the small-bowel mucosa. Generally, all oral rehydration solutions contain sodium and potassium to promote fluid uptake and replacement of major electrolytes lost. |
| Drug Indication | Dehydration (treatment and prophylaxis) |
| Precautions | Severe dehydration requires parenteral rehydration. |
| Contra-Indications | Anuria; oliguria; glucose malabsorption; very severe diarhoea; inability to drink; severe and sustained vomiting, intestinal obstruction, paralytic ileus, perforated bowel. |
| Side Effects | Hypernatremia; puffy eyelids; mild vomiting |
| Dosage | According to the extent of fluid loss. Usually 200 - 400ml solution after every loose motion. Infant: 1-1½ times usual feed volume. Children: 200ml after every loose motion. |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Haematinics |